Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
inotersen
5
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
fda
patisiran
tafamidis
alnylam pharmaceuticals
boston
clinical trials
drugs
hereditary transthyretin amyloidosis
onpattro
pfizer
san francisco blog main
san francisco top stories
biotech
rna interference
tegsedi
transthyretin amyloidosis
vyndaqel
2025
ad-comm
affimed
allogene therapeutics
amicus therapeutics
andrew fire
anylam pharmaceuticals
approval
apremilast
barry greene
base editing
bio
What
alnylam
fda
drug
medicine
ago
approved
patients
rna
rnai
uses
afternoon
akcea
allogene
alnylam’s
amyloidosis
approve
approves
attr
available
awaits
battle
bio
biological
cancer
cells
crispr
crossed
debilitating
decades
decision
discovered
disease
diversity
ema
employ
europe
fingers
follows
friday
gene
Language
Current search:
inotersen
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision